Antimicrobials
DAPTOmycin

DAPTOmycin

Restricted

Low
N/A
$$$

Spectrum of Activity

Dosing

General Information

Targeted therapy of resistant gram positive infections with:

  • MRSA or other Gram-positive infections in patients who cannot receive 1st line agents

  • Vancomycin Resistant Enterococcus

Note:

  • DO NOT use for pneumonia, inactivated by pulmonary surfactant
  • Creatine kinase at baseline and weekly during prolonged therapy. Consider stopping statin while on therapy.
  • Monitor for signs/symptoms of eosinophilic pneumonia (see adverse effects)
  • Myopathy including rhabdomyolysis
  • GI side effects common
  • Rash
  • Phlebitis
  • Increased INR
  • Eosinophilic pneumonia
    • Rare but serious adverse event typically presenting as fever and/or dyspnea with increased oxygen requirements. Presentation can be variable and may not include respiratory symptoms. 
    • Evaluate patient and consider holding daptomycin if unexplained fever, new onset or worsening cough, dyspnea and/or peripheral eosinophilia.

Statins and fibrates - Increased myopathy. Monitor creatine kinase or hold while on daptomycin therapy.

Antimicrobial class: Cyclic Lipopeptide.

Pregnancy category: B

Average serum half life: 9 hours

Urine penetration: Therapeutic

Lung penetration: Poor

CSF penetration: Poor

  • Can obtain sensitivities on request

  • Higher doses used for endovascular infection.

  • Recommend Infectious Disease Consult.

  • Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.